Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
|
Total sales from the HIV franchise were $19.6
billion in 2024, up 8% year over year, driven by strong growth in lead HIV
treatment Biktarvy. GILD ... |
Impact of US funding cuts on HIV programmes in Angola
While stocks of antiretroviral supplies, HIV, viral load and other lab test kits are available, recent reports indicate challenges with distribution. View article...